The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety…
Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI PlatformBOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Quris-AI…
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics…
BRECKENRIDGE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S. and a…
NEW YORK and LONDON and SAO PAOLO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed…
Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after…
Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on…
Japanese Patent Represents FendX's 4th Patent IssuedOakville, Ontario--(Newsfile Corp. - October 29, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB:…
NEW PROVIDENCE, N.J., Oct. 29, 2024 /PRNewswire/ -- Evolution Research Group (ERG) and Lotus, portfolio companies of Emerge HoldCo, LLC, in…
Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers…